Mirum Pharmaceuticals, Inc. Quarterly Debt-to-equity in % from Q1 2020 to Q2 2024

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Mirum Pharmaceuticals, Inc. quarterly Debt-to-equity history and growth rate from Q1 2020 to Q2 2024.
  • Mirum Pharmaceuticals, Inc. Debt-to-equity for the quarter ending June 30, 2024 was 166 %, a 8.5% decline year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q2 2024 166 -15.4 -8.5% Jun 30, 2024
Q1 2024 188 +48.6 +34.9% Mar 31, 2024
Q4 2023 181 +37.8 +26.4% Dec 31, 2023
Q3 2023 182 +39.8 +27.9% Sep 30, 2023
Q2 2023 181 +2.45 +1.37% Jun 30, 2023
Q1 2023 139 -37.5 -21.2% Mar 31, 2023
Q4 2022 143 -2.64 -1.81% Dec 31, 2022
Q3 2022 142 +36 +33.8% Sep 30, 2022
Q2 2022 179 +116 +182% Jun 30, 2022
Q1 2022 177 +142 +402% Mar 31, 2022
Q4 2021 146 +124 +575% Dec 31, 2021
Q3 2021 106 +92.8 +679% Sep 30, 2021
Q2 2021 63.4 +52 +457% Jun 30, 2021
Q1 2021 35.3 +20.8 +144% Mar 31, 2021
Q4 2020 21.7 Dec 31, 2020
Q3 2020 13.7 Sep 30, 2020
Q2 2020 11.4 Jun 30, 2020
Q1 2020 14.5 Mar 31, 2020
* An asterisk sign (*) next to the value indicates that the value is likely invalid.